Life Science Investing AMGEN MAKES REPATHA® AVAILABLE THROUGH AMGENNOW, A DIRECT-TO-PATIENT PROGRAM IN THE U.S. 06 October
Life Science Investing LANDMARK PHASE 3 TRIAL MEETS PRIMARY ENDPOINTS IN A CARDIOVASCULAR PRIMARY PREVENTION STUDY OF 12,000 PATIENTS 02 October
